BUSINESS: Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, And Growth Prospects Analysis | DelveInsight

dWeb.News Article from Daniel Webster dWeb.News

dWeb.News Article from Daniel Webster dWeb.News

By Daniel Webster, dWeb.News Publisher

Las Vegas, USA, Oct. 11, 2021 (GLOBE NEWSWIRE) — Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis | DelveInsight

Approximately 22+ key companies are developing therapies for Acne Vulgaris. Some of the major key players developing therapies to treat acne vulgaris are Bausch Health Companies, BioPharmX Corporation, Boston Pharmaceuticals, Eligo Bioscience, Suzhou Kintor Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, and others.

DelveInsight’s ‘Acne Vulgaris Pipeline Insight 2021’ report offers detailed coverage of available, marketed, and pipeline therapies being clinically developed, key companies working to advance the pipeline space, and future growth potential of the Acne Vulgaris pipeline domain. 

Some of the major pointers from the Acne Vulgaris Pipeline report:

DelveInsight’s Acne Vulgaris Pipeline analysis depicts the space with 22+ active players working to develop 22+ pipeline therapies. 
Major pharmaceutical companies are developing potential drug candidates to improve the Acne Vulgaris treatment scenario, such as BOS-356, Imsidolimab, Aminolevulinic acid (ALA), IDP-126, BTX 1503, FCD 105, GT 20029,  and others.
Key pharmaceutical companies involved in the development of therapies to treat acne vulgaris are Bausch Health Companies, Botanix Pharmaceuticals, Boston Pharmaceuticals, Eligo Bioscience, Suzhou Kintor Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, BioPharmX Corporation, AnaptysBio, VYNE Therapeutics, and others.
In December 2020, Sol-Gel Technologies announced that their New Drug Application (NDA) for Twyneo for the treatment of acne vulgaris, has been accepted for filing by the U.S. Food and Drug Administration (FDA). 
In January 2021, Eligo Bioscience SA (Eligo) announced that it had entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutics for strain-specific microbiome modulation.
BioPharmX is developing a novel, proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. The product is the first candidate from the company’s anhydrous hydrophilic topical delivery system and in our formulation, the minocycline is completely solubilized. The formulation is currently in clinical development for patients with inflammatory lesions of acne vulgaris.
In April 2021, Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced that the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.
In April 2021, Bausch Health Companies Inc., and its dermatology business, Ortho Dermatologics, announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating its investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical, to treat acne vulgaris in patients nine years of age and older.

Know which pharma company is anticipated to take charge of Acne Vulgaris pipeline in the coming years by requesting a sample @ Acne Vulgaris Emerging Therapies and Forecast 

The Acne Vulgaris pipeline report lays down detailed profiles of the pipeline assets,  inactive and dormant assets, comparative analysis of clinical and non-clinical stage Acne Vulgaris products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Acne Vulgaris pipeline landscape.

Acne Vulgaris Overview

Acne Vulgaris is considered as an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. It is classified into different forms which vary in severity, lesion type, and localization. It is a very common skin disorder that can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. 

Acne vulgaris symptoms can be mild, moderate, or severe and are diagnosed clinically and Acne Vulgaris treatment is based on severity and can involve a variety of topical and systemic agents directed at reducing sebum production, comedone formation, inflammation, and bacterial counts and at normalizing keratinization.

Discover more about the therapeutic scenario in Acne Vulgaris @ Acne Vulgaris Emerging Therapies 

Acne Vulgaris Pipeline Drugs

Drug
Company
Phase
MoA
RoA
IDP-126
Bausch Health Americas, Inc.
Phase III
Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors
Topical
FCD 105
VYNE Therapeutics
Phase II
Glial cell inhibitors; Interleukin 1 alpha inhibitors
Topical
BTX 1503
Botanix Pharmaceuticals
Phase II
Cannabinoid receptor CB1 inverse agonists
Topical
Imsidolimab
AnaptysBio
Phase II
Interleukin 36 receptor antagonists
Intravenous; Subcutaneous
Aminolevulinic acid (ALA)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Phase I/II
Photosensitisers
Topical
GT 20029
Suzhou Kintor Pharmaceuticals
Phase I
Androgen receptor degradation enhancers
Topical
BOS-356
Boston Pharmaceuticals
Phase I
Diacylglycerol O acyltransferase inhibitors
Topical

Explore the scope of Acne Vulgaris pipeline therapies @ Acne Vulgaris Pipeline Analysis

Acne Vulgaris Therapeutics Assessment

The Acne Vulgaris Pipeline report proffers an integral view of the Acne Vulgaris emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.

By Product Type

Mono
Combination
Mono/Combination

By Stage

Discovery 
Pre-clinical
Phase I
Phase II
Phase III
Pre-registration

By Route of Administration

Oral
Parenteral
Intravenous
Subcutaneous
Topical

By Molecule Type 

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

By Mechanism of Action

Keratinocyte inhibitors
Protein 50S ribosomal subunit inhibitors
Glial cell inhibitors; Interleukin 1 alpha inhibitors
Interleukin 36 receptor antagonists
Diacylglycerol O acyltransferase inhibitors
Androgen receptor degradation enhancers

Scope of the Acne Vulgaris Pipeline Report 

Coverage: Global 
Major Players: Bausch Health Companies, Boston Pharmaceuticals, Eligo Bioscience, Suzhou Kintor Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, VYNE Therapeutics, Botanix Pharmaceuticals, BioPharmX Corporation, and others.
Key Acne Vulgaris Pipeline Therapies: IDP-126, FCD 105, BTX 1503, Imsidolimab, Aminolevulinic acid, GT 20029, BOS-356, BPX-01, and others.

Learn more about the report offerings @ Acne Vulgaris Pipeline Emerging Novel Therapies 

Table of Contents 

1
Introduction
2
Executive Summary
3
Acne Vulgaris: Overview
4
Pipeline Therapeutics
5
Therapeutic Assessment
6
Acne vulgaris – DelveInsight’s Analytical Perspective
7
Late Stage Products (Phase III)
8
Mid Stage Products (Phase II/III)
9
Early Stage Products (Phase I)
10
Preclinical/Discovery Stage Products
11
Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Acne Vulgaris Key Companies
14
Acne Vulgaris Key Products
15
Acne Vulgaris- Unmet Needs
16
Acne Vulgaris- Market Drivers and Barriers
17
Acne Vulgaris- Future Perspectives and Conclusion
18
Acne Vulgaris Analyst Views
19
Appendix
20
About DelveInsight

Get Acne Vulgaris customized report @ Acne Vulgaris Emerging Therapies 

Track candidate’s clinical development journey here @ Profiling and Comparative Therapeutic Assessment

Related Reports

Acne Vulgaris Market

DelveInsight’s “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris market trends, current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Moderate to Severe Inflammatory Acne Vulgaris Market 

DelveInsight’s “Moderate to Severe Inflammatory Acne Vulgaris – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Moderate to Severe Inflammatory Acne Vulgaris, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market

DelveInsight’s “Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology, treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Acne vulgaris Epidemiology

DelveInsight’s ‘Acne vulgaris – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Moderate to Severe Inflammatory Acne Vulgaris Epidemiology 

DelveInsight’s ‘Moderate to Severe Inflammatory Acne Vulgaris – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Moderate to Severe Inflammatory Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Epidemiology

DelveInsight’s ‘Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline

“Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market. A detailed picture of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline landscape is provided.

Moderate to Severe Inflammatory Acne Vulgaris Pipeline

“Moderate to Severe Inflammatory Acne Vulgaris Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Moderate to Severe Inflammatory Acne Vulgaris market. A detailed picture of the Moderate to Severe Inflammatory Acne Vulgaris pipeline landscape is provided.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline

“Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market. A detailed picture of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline landscape is provided.

Browse Through Our Blog Posts

Acne Vulgaris Market Outlook

Acne Vulgaris (AV) is one of the most common dermatological conditions worldwide and is a chronic skin disease/disorder of pilosebaceous follicles. 

Do We Have A Cure For Rosacea?

Awareness about any condition is as important as treating the condition itself. Similar is the case with, Rosacea, a characteristic inflammatory condition affecting the skin especially the face resulting in facial erythema or redness. 

AnaptysBio’s shares plummeted after its lead drug fails in rare skin inflammation phase II trial 

AnaptysBio shares fell owing to discouraging news of its antibody-drug, imsidolimab, failure in a rare inflammatory skin condition. The company announced that the drug did not prove to be upbeat.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

For more dWeb.News Business News: https://dweb.news/news-sections/business-news/

The post BUSINESS: Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, And Growth Prospects Analysis | DelveInsight appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

The post BUSINESS: Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, And Growth Prospects Analysis | DelveInsight appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

Read More

Section C Consumer Products Retail News – dWeb.News

More Consumer Products Retail News at https://dweb.news/category/dweb-news/section-c-consumer-products-retail-news/

Similar Posts